News & Events
10 May 2012 DIABETES AT THE COALFACE
Following on from the success of last year’s event, I am delighted to announce that the Welsh Conference of the Primary Care Diabetes Society will be held again in Cardiff on 10 May this year.
Hosted by Dr Pam Brown and Dr David Millar-Jones, Welsh representatives of the PCDS, this event will provide you with continuing professional development, an opportunity to learn from some leading diabetes experts in Wales and a chance to network with your peers and discuss the key issues that affect you in day-to-day clinical practice.
Through lectures and interactive masterclasses this event will provide practical guidance to healthcare professionals on issues that impact everyday diabetes practice in Wales. Entitled “Diabetes at the Coalface – Management strategies for type 2 diabetes in Wales”, this year’s event covers topics including:
- Diagnosing diabetes and how to screen for it
- Diabetes therapies: out with the old and in with the new?
- Obesity: a Welsh perspective
New resources due to be launched before this year’s conference will also provide you with extended CPD opportunities, such as online post-event education and tools to help you put in place action plans within your practice.
This cost to attend this event this year has been reduced to £75 for PCDS members* and £95 for non-members. However, by booking before 29 February, you can take advantage of the of the early-bird price of £60 and £75 respectively.
For more information or to book on this exciting conference please click here or call the events team on: 0207 627 1510.
We hope that you will be able to join us at this important and influential event.
Abnormal levels of age-elastin derived peptides in sera of diabetic patients with arterial hypertension
The measurement of non-invasive markers of elastin glycation may be useful in monitoring development of vascular wall alterations and therapeutic interventions (Central European Journal of Immunology)
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes
Demonstrates Proof-of-Concept for ORMD-0801 Oral Insulin to Reduce Exogenous Insulin Requirements (Oramed Pharmaceuticals)
Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case–control study
This study shows that treatment with CSII resulted in an improvement in HbA1c levels up to 1yr and decreased the number of severe hypoglycaemic events, but the frequency of ketoacidosis increased (Pediatric Diabetes)
Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care
Clinical trials show superior glycaemic control and weight reduction with liraglutide compared with sitagliptin. This finding is reflected in routine clinical practice in the UK (International Journal of Clinical Practice)
Targets and Candidate Agents for Type 2 Diabetes Treatment with Computational Bioinformatics Approach
In the present study, a systematic understanding for the mechanism underlying T2D development was provided with biological informatics methods. The significant nodes and bioactive small molecules may be drug targets and candidate agents for T2D treatment (Journal of Diabetes Research)